Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1642 1652 1654 1671
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18359569 | LDL RECEPTOR-DIRECTED BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS | Non-Final OA | The Regents of the University of California |
| 18030223 | ENHANCEMENT OF ANTI-TUMOR PHAGOCYTOSIS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18193917 | METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 18528327 | NATURAL KILLER T CELL LIGAND LOADED EXTRACELLULAR NANOVESICLE AND AUTOLOGOUS ANTI-CANCER VACCINE FOR HEMATOLOGIC MALIGNANCIES COMPRISING THE SAME | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18010580 | BIOMARKER BASED PATIENT SELECTION FOR PROTEASOME INHIBITOR TREATMENT | Non-Final OA | University of Utah Research Foundation |
| 17753632 | TREATMENT OF RMS BY SWITCHING THERAPY | Non-Final OA | Novartis AG |
| 18547644 | COMPOSITIONS AND METHODS FOR STABILIZATION OF ALLOSTERIC PROTEINS | Final Rejection | UNIVERSITY OF WASHINGTON |
| 17294401 | COMPOSITIONS AND METHODS FOR THE CYTOPLASMIC DELIVERY OF ANTIBODIES AND OTHER PROTEINS | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18238153 | CONTORSBODY - A SINGLE CHAIN TARGET BINDER | Final Rejection | Hoffmann-La Roche Inc. |
| 17918479 | TARGETING ABCB5 IN GLIOBLASTOMA MULTIFORME | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18549346 | MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN THERAPY | Non-Final OA | BIONTECH SE |
| 18282664 | POLYPEPTIDES FOR COMPLEMENT INHIBITION | Non-Final OA | Apellis Pharmaceuticals, Inc. |
| 18029400 | EGFR-TARGETING CHIMERIC ANTIGEN RECEPTOR | Final Rejection | BEIJING INSTITUTE FOR STEM CELL AND REGENERATIVE MEDICINE |
| 18026373 | BISPECIFIC RECOMBINANT PROTEIN AND USE THEREOF | Non-Final OA | SHANGHAI LYN-CREST ENTERPRISE MANAGEMENT CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy